TY - JOUR
T1 - Effect of Multiple HLA Locus Mismatches on Outcomes after Single Cord Blood Transplantation
AU - Japanese Society for Transplantation and Cellular Therapy's HLA Working Group
AU - Kanda, Junya
AU - Hirabayashi, Shigeki
AU - Yokoyama, Hisayuki
AU - Kawase, Takakazu
AU - Tanaka, Hidenori
AU - Uchida, Naoyuki
AU - Taniguchi, Shuichi
AU - Takahashi, Satoshi
AU - Onizuka, Makoto
AU - Tanaka, Masatsugu
AU - Sugio, Yasuhiro
AU - Eto, Tetsuya
AU - Kanda, Yoshinobu
AU - Kimura, Takafumi
AU - Ichinohe, Tatsuo
AU - Atsuta, Yoshiko
AU - Morishima, Satoko
N1 - Funding Information:
Financial disclosure: This work was supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from the Japan Agency for Medical Research and Development (to Y.A. and J.K.) and Japan Society for the Promotion of Science KAKENHI Grant 21K08391 (to J.K.).
Publisher Copyright:
© 2022 The American Society for Transplantation and Cellular Therapy
PY - 2022/7
Y1 - 2022/7
N2 - The effect of single or multiple mismatches at each HLA locus on outcomes after cord blood transplantation (CBT) is controversial. We analyzed the effects of single or multiple HLA locus mismatches on the outcomes after single CBT using Japanese registry data from the Japan Society for Hematopoietic Cell Transplantation. Patients age ≥16 years with acute leukemia and myelodysplastic syndromes who underwent their first CBT between 2003 and 2017 (n = 4074) were included. The effect of the number of HLA locus mismatches (0, 1, or 2 for the HLA-A, -B, -C, and -DRB1 loci) on outcomes was analyzed after adjusting for other significant variables. The patient cohort had a median age of 54 years. The median total nucleated and CD34 cell doses were 2.6 × 107/kg and .8 × 105/kg, respectively. The number of CBTs with single or double mismatches were 2099 and 292, respectively, for the HLA-A locus, 2699 and 341 for the HLA-B locus, 2555 and 609 for the HLA-C locus, and 2593 and 571 for the HLA-DRB1 locus. Single and double HLA-DRB1 mismatches were associated with a higher risk of grade II-IV acute graft-versus-host disease (GVHD; single: hazard ratio [HR], 1.29, P < .001; double: HR, 1.49, P < .001; P for trend <.001). Single and double mismatches at HLA-DRB1 as well as single mismatches at HLA-A and HLA-B also were associated with grade III-IV acute GVHD. Single and double HLA-B mismatches and double HLA-DRB1 mismatches were associated with a high risk of nonrelapse mortality (NRM). On the other hand, double mismatches at HLA-A or HLA-DRB1 and single mismatches at HLA-B were associated with a lower risk of relapse. HLA-DRB1 double mismatch was associated with high risk of grade II-IV and grade III-IV acute GVHD and NRM but lower risk of relapse. Not only the locus mismatch, but also the number of mismatches, should be considered in cord blood unit selection.
AB - The effect of single or multiple mismatches at each HLA locus on outcomes after cord blood transplantation (CBT) is controversial. We analyzed the effects of single or multiple HLA locus mismatches on the outcomes after single CBT using Japanese registry data from the Japan Society for Hematopoietic Cell Transplantation. Patients age ≥16 years with acute leukemia and myelodysplastic syndromes who underwent their first CBT between 2003 and 2017 (n = 4074) were included. The effect of the number of HLA locus mismatches (0, 1, or 2 for the HLA-A, -B, -C, and -DRB1 loci) on outcomes was analyzed after adjusting for other significant variables. The patient cohort had a median age of 54 years. The median total nucleated and CD34 cell doses were 2.6 × 107/kg and .8 × 105/kg, respectively. The number of CBTs with single or double mismatches were 2099 and 292, respectively, for the HLA-A locus, 2699 and 341 for the HLA-B locus, 2555 and 609 for the HLA-C locus, and 2593 and 571 for the HLA-DRB1 locus. Single and double HLA-DRB1 mismatches were associated with a higher risk of grade II-IV acute graft-versus-host disease (GVHD; single: hazard ratio [HR], 1.29, P < .001; double: HR, 1.49, P < .001; P for trend <.001). Single and double mismatches at HLA-DRB1 as well as single mismatches at HLA-A and HLA-B also were associated with grade III-IV acute GVHD. Single and double HLA-B mismatches and double HLA-DRB1 mismatches were associated with a high risk of nonrelapse mortality (NRM). On the other hand, double mismatches at HLA-A or HLA-DRB1 and single mismatches at HLA-B were associated with a lower risk of relapse. HLA-DRB1 double mismatch was associated with high risk of grade II-IV and grade III-IV acute GVHD and NRM but lower risk of relapse. Not only the locus mismatch, but also the number of mismatches, should be considered in cord blood unit selection.
UR - http://www.scopus.com/inward/record.url?scp=85132392585&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132392585&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2022.05.005
DO - 10.1016/j.jtct.2022.05.005
M3 - Article
C2 - 35577322
AN - SCOPUS:85132392585
SN - 2666-6375
VL - 28
SP - 398.e1-398.e9
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 7
ER -